Tag: Potassium competitive acid blocker

Millions of Americans experience chronic heartburn associated with GERD, often finding traditional treatments like proton pump inhibitors (PPIs) provide insufficient relief. A significant advancement has recently addressed this gap: the FDA has approved Voquezna (vonoprazan), answering the question, 'What is the new drug for GERD?'.

According to Mayo Clinic, vonoprazan was approved for use in the U.S. in late 2023 for adults. **What is the use of Vocid Tablet?** This prescription medication, containing the active ingredient vonoprazan, is primarily used to treat and manage various gastrointestinal conditions caused by excessive stomach acid, such as erosive esophagitis and stomach ulcers.

Affecting approximately 65 million people in the United States, gastroesophageal reflux disease (GERD) is a chronic condition causing significant discomfort. The recent FDA approval of vonoprazan (Voquezna) offers an answer to the question, "**what is the new medicine for acid reflux?**", marking the first major innovation in this area in over 30 years. This new class of medication, known as a potassium-competitive acid blocker (P-CAB), works differently from standard treatments to provide faster and more sustained relief.